Network News
Ruperto Carola in 59th place worldwide – among the “Top 3” in Germany Heidelberg University has achieved top placements in the 2026 Academic Ranking of World Universities. As in the previous year, it is one of the “Top 3” universities in Germany. In the global comparison, Ruperto Carola is in 59th position in this so-called […]
read moreDonation of over 107,000 euros for sick and underprivileged children
As part of the 23rd annual global charity run, the “Roche Children’s Walk,” numerous Roche employees throughout Germany participated in a variety of running, sports, and recreational activities. At the Grenzach-Wyhlen, Mannheim, Penzberg, and Ludwigsburg sites, a total of 53,875 euros was raised. With the German Roche companies matching this amount for global aid projects, […]
read more
VectorBuilder and Lir Therapeutics Partner to Advance AAV Capsids Designed for Clinical Success
CHICAGO – August 18, 2026 – VectorBuilder, a global leader in gene delivery technologies, and Lir Therapeutics, a company pushing the boundaries of vector engineering with AI, today announced a strategic collaboration to develop adeno-associated virus (AAV) capsids designed not only for strong biological performance, but also for the manufacturability and scalability required to bring gene […]
read more
Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026
COPENHAGEN, Denmark, Aug. 06, 2026 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report second quarter 2026 financial results and provide a business update on Thursday, August 13, 2026, before the open of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on August 13, 2026, at 8:00 a.m. Eastern Time (ET) to discuss […]
read more
Can Protein Building Blocks Protect Against Vascular and Kidney Damage?
Researchers from the Medical Faculty Heidelberg, the Medical Faculty Mannheim, and the Centre for Organismal Studies (COS) at Heidelberg University have launched a new research project investigating so-called dipeptides. Some of these naturally occurring protein building blocks are able to neutralize toxic metabolic by-products and may therefore help protect against vascular and kidney damage, particularly […]
read more
The University Hospital Cologne (UHC), in collaboration with the German Center for Infection Research (DZIF) has selected the Celonic Group for process development and GMP manufacturing of a monoclonal antibody targeting Pseudomonas aeruginosa.
Basel, Switzerland / Köln, Germany August 12, 2026 The University Hospital Cologne (Universitätsklinikum Köln, UHC) has chosen the Celonic Group as its CDMO partner for advanced process development and GMP manufacturing of its monoclonal antibody targeting Pseudomonas aeruginosa, a Gram‑negative pathogen responsible for severe hospital‑acquired infections, biofilm‑driven persistence, and rising antimicrobial resistance. The antibody program is […]
read more
Center of Excellence in Oncology: NCT Heidelberg and Mannheim Cancer Center Receive Joint Funding
Joint Press Release from NCT Heidelberg and Mannheim University Medical Center The National Center for Tumor Diseases (NCT) Heidelberg and the Mannheim Cancer Center (MCC) are receiving joint funding as a Center of Excellence in Oncology for the first time. German Cancer Aid is providing 4.8 million euros over four years for the new consortium. […]
read more
Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease
Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease Paris, August 4, 2026. Sanofi today announced that the European Commission (EC) has approved an extension of the indication for MenQuadfi (Meningococcal Group A, C, W and Y conjugate vaccine) to include infants from six weeks of age […]
read more
Merck Opens BioReliance® Facility in Darmstadt to Support Drug Product Release in Europe
Merck opens a €25M testing facility at its Darmstadt headquarters, strengthening drug release testing for European biopharmaceutical markets. 16 Jul 2026 | Darmstadt, Germany Merck, a leading science and technology company, today opened a new €25 million BioReliance® testing facility at its global headquarters in Darmstadt, Germany. The facility expands access to commercial drug substance and drug product […]
read more
